References
- World Health OrganizationFact sheet 312 – DiabetesGeneva, SwitzerlandWorld Health Organization2011 Available from: http://www.who.int/mediacentre/factsheets/fs312/en/Accessed December 19, 2013
- International Diabetes FederationIDF Diabetes Atlas6th edBrussels, BelgiumInternational Diabetes Federation2013 Available from: http://www.idf.org/diabetesatlasAccessed December 19, 2013
- JonssonBCODE-2 Advisory BoardRevealing the cost of type II diabetes in EuropeDiabetologia2002457S5S1212136405
- International Diabetes Federation Clinical Guidelines Task ForceGlobal guideline for type 2 diabetesBrussels, BelgiumInternational Diabetes Federation2005 Available from: http://www.idf.org/global-guideline-type-2-diabetes-2005Accessed December 19, 2013
- InzucchiSEBergenstalRMBuseJBManagement of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)Diabetes Care20123561364137922517736
- BuseJBRosenstockJSestiGLiraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)Lancet20093749683394719515413
- European Medicines AgencySummary of Product Characteristics – Byetta2013 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000698/WC500051845.pdfAccessed December 19, 2013
- European Medicines AgencySummary of Product Characteristics – Victoza2013 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001026/WC500050017.pdfAccessed December 19, 2013
- IMS Xponent Dynamic Prescription Data (Oct 2008–Jun 2011)UKProprietary IMS data on file2011
- IMS Xponent Longitudinal Prescription Data (Oct 2007–May 2011)The NetherlandsProprietary IMS data on file2011
- IMS Xponent Longitudinal Prescription Data (Apr 2007–May 2011)GermanyProprietary IMS data on file2011
- IMS Sales DataIMS2011
- FuchsSKostevKSeitzLWohllebenMErmittlung der tatsächlichen Tagesdosierung von Liraglutid (PDD) unter realen Versorgungsbedingungen im Hinblick auf die Berechnung von Tagestherapiekosten [Identification of the Prescribed Daily Dose (PDD) using the example of Liraglutide with regard to defining daily therapy costs]. 46. Jahrestagung der Deutschen-Diabetes-Gesellschaft46th Annual Meeting of the German Diabetes SocietyJune 1–4, 2011Leipzig, Germany
- BestJHLavillottiKDeYoungMBGarrisonLPThe effects of exenatide bid on metabolic control, medication use and hospitalization in patients with type 2 diabetes mellitus in clinical practice: a systematic reviewDiabetes Obes Metab201214538739822074017
- IMS Pharmacy Panel (The Netherlands)IMS Health2011
- Royal Pharmaceutical SocietyMedicinesComplete Available from: https://www.medicinescomplete.comAccessed March 19, 2012